747 related articles for article (PubMed ID: 23514959)
1. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.
Freitas MC; Rebellato LM; Ozawa M; Nguyen A; Sasaki N; Everly M; Briley KP; Haisch CE; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
Transplantation; 2013 May; 95(9):1113-9. PubMed ID: 23514959
[TBL] [Abstract][Full Text] [Related]
2. Post-transplant development of C1q-positive HLA antibodies and kidney graft survival.
Piazza A; Poggi E; Ozzella G; Adorno D
Clin Transpl; 2013; ():367-75. PubMed ID: 25095531
[TBL] [Abstract][Full Text] [Related]
3. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
Transpl Int; 2017 Apr; 30(4):347-359. PubMed ID: 27717025
[TBL] [Abstract][Full Text] [Related]
4. De novo donor specific antibodies and patient outcomes in renal transplantation.
DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
[TBL] [Abstract][Full Text] [Related]
5. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.
Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM
Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
[TBL] [Abstract][Full Text] [Related]
7. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
[TBL] [Abstract][Full Text] [Related]
8. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy.
Willicombe M; Brookes P; Sergeant R; Santos-Nunez E; Steggar C; Galliford J; McLean A; Cook TH; Cairns T; Roufosse C; Taube D
Transplantation; 2012 Jul; 94(2):172-7. PubMed ID: 22735711
[TBL] [Abstract][Full Text] [Related]
9. DQ molecules are the principal stimulators of de novo donor-specific antibodies in nonsensitized pediatric recipients receiving a first kidney transplant.
Tagliamacco A; Cioni M; Comoli P; Ramondetta M; Brambilla C; Trivelli A; Magnasco A; Biticchi R; Fontana I; Dulbecco P; Palombo D; Klersy C; Ghiggeri GM; Ginevri F; Cardillo M; Nocera A
Transpl Int; 2014 Jul; 27(7):667-73. PubMed ID: 24629017
[TBL] [Abstract][Full Text] [Related]
10. Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing.
Süsal C; Wettstein D; Döhler B; Morath C; Ruhenstroth A; Scherer S; Tran TH; Gombos P; Schemmer P; Wagner E; Fehr T; Živčić-Ćosić S; Balen S; Weimer R; Slavcev A; Bösmüller C; Norman DJ; Zeier M; Opelz G;
Transplantation; 2015 Sep; 99(9):1976-80. PubMed ID: 25769065
[TBL] [Abstract][Full Text] [Related]
11. Significance of C1q-fixing donor-specific antibodies after kidney transplantation.
Thammanichanond D; Mongkolsuk T; Rattanasiri S; Kantachuvesiri S; Worawichawong S; Jirasiritham S; Kitpoka P
Transplant Proc; 2014; 46(2):368-71. PubMed ID: 24655965
[TBL] [Abstract][Full Text] [Related]
12. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN
Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
[TBL] [Abstract][Full Text] [Related]
14. Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies.
Arnold ML; Ntokou IS; Doxiadis II; Spriewald BM; Boletis JN; Iniotaki AG
Transpl Int; 2014 Mar; 27(3):253-61. PubMed ID: 24118579
[TBL] [Abstract][Full Text] [Related]
15. Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival.
Guidicelli G; Guerville F; Lepreux S; Wiebe C; Thaunat O; Dubois V; Visentin J; Bachelet T; Morelon E; Nickerson P; Merville P; Taupin JL; Couzi L
J Am Soc Nephrol; 2016 Feb; 27(2):615-25. PubMed ID: 26047793
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
[TBL] [Abstract][Full Text] [Related]
18. Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation.
Wozniak LJ; Hickey MJ; Venick RS; Vargas JH; Farmer DG; Busuttil RW; McDiarmid SV; Reed EF
Transplantation; 2015 Jul; 99(7):1416-22. PubMed ID: 26038872
[TBL] [Abstract][Full Text] [Related]
19. Donor-specific antibody to trans-encoded donor HLA-DQ heterodimer.
Habig DF; Gaspari JL; Lokhandwala PM; Domen RE; Abendroth CS; Kadry Z; Ghahramani N; Shah RA; Jain A; Shike H
Hum Immunol; 2015 Aug; 76(8):587-90. PubMed ID: 26382246
[TBL] [Abstract][Full Text] [Related]
20. Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients.
Lee H; Min JW; Kim JI; Moon IS; Park KH; Yang CW; Chung BH; Oh EJ
Medicine (Baltimore); 2016 Mar; 95(11):e3094. PubMed ID: 26986147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
